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ABSTRACT
On March 12, 2020, The World Health Organization (WHO) announced the new coronavirus
2019 as a global pandemic. In January 2022, the number of COVID-19 cases reached 300
million confirmed cases with a total death count of 5.5 million cases. Severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2) was identified in a seafood wholesale market in Wuhan,
China. At the time of the outbreak, there was no effective treatment to protect from the novel
coronavirus; the only way to control the pandemic was through reducing person-to-person
contact and taking preventive measures based on the severity of the disease among the
population. The first aim of this thesis is to visualize the confirmed, deaths, and recovered cases
across the most affected countries and to analyze if non-pharmaceutical interventions (NPI), such
as government interventions, are effective in flattening the curve. The second aim of this thesis is
to use machine learning models to predict the severity of COVID-19 and clinical outcomes based
on demographic, epidemiological, comorbidities, and laboratory findings among the Egyptian
population during the lockdown period.
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Chapter 1: Literature Review & Study Objectives
1.1 Etiology
On December 31, 2019, the World Health Organization (WHO) was informed of an outbreak of
pneumonia of an unknown cause detected in Wuhan, China. The infectious agent was a virus of
the coronavirus family SARS-CoV-2, which causes a respiratory disease termed COVID-19. In
Wuhan China, in December 2019, several unexplained pneumonia symptoms showed in a group
of people who were in direct contact at a seafood wholesale market (1). Thereafter, some of
those patients showing pneumonia symptoms were admitted to a hospital in Wuhan, China. On
December 30, 2019, in Wuhan Jinyintan Hospital the detection of the novel virus was done
through the collection of bronchoalveolar-lavage samples (1). On March 12, 2020, the World
Health Organization announced COVID-19 as a global pandemic (3).

WHO informed of an outbreak
30 December 2019

5 January 2020
31 December 2019

Detection of a novel virus

WHO declaration of
COVID 19

WHO announces COVID
19 as pandemic

12 March 2020

Figure 1. COVID-19 Timeline. The timeline of the events of Covid-19 from the discovery of the virus
to the announcement of the virus as a pandemic.

The initial source of transmission of coronavirus is still unknown, however, it is proposed that
the likely route for spreading COVID-19 infection is through person-to-person transmission.
This transmission occurs through close contact or through droplets spread by sneezing or
coughing from an infected or carrier person (1).

1.1.1 History
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As of January 12, 2022, coronavirus has affected more than 300 million people worldwide with a
total deaths of 5.5 million (2). Several countries have been greatly affected by the novel virus
resulting in millions of fatalities. This was due to geographic location, unpreparedness to the new
pandemic, age distribution of the population, cultural behavior, government regulations, and risk
factors present in those countries. Most data have shown that older age and male gender are
critical factors that entail the severity of the disease, acting as a predisposing factor that
contributes to the complication of the case (3).

1.1.2 Virus Classification
Coronaviruses belong to the family of viruses called Coronaviridae in the order Nidovirales, and
Coronavirinae and Torovirinae make up the Coronaviridae family (4). The Coronavirinae are
classified into four genera Alphacoronavirus (Alpha-CoV), Betacoronavirus (Beta-CoV),
Deltacoronavirus (delta-CoV), and Gammacoronavirus (Gamma-CoV) are the four genera of
Coronavirinae, while Torovirus and Bafinivirus are the two genera of Torovirinae (5). Human
coronaviruses belong to the alpha and beta coronavirus genus. Severe acute respiratory syndrome
(SARS) and Middle East Respiratory Syndrome (MERS) coronaviruses belong to beta
coronaviruses. They are found in both humans, mammals, and birds. Only seven strains of the
coronavirus exist, all of which are zoonotic pathogens; that is, they originate in infected
animals and get transmitted from animals to humans causing disease (6). SARS-CoV-2,
MERS-CoV, and SARS-CoV are three of the seven coronaviruses which are of high
pathogenicity, causing respiratory infections in humans and resulting in severe outcomes which
could be fatal (7). In recent decades, the identified coronavirus strains have manifested in the
form of two main outbreaks: the first was in 2002 and was caused by the SARS virus while the
second was in 2012 and was caused by the MERS virus. There was a total of 8,000 SARS-CoV
14
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cases with a case fatality rate (CFR) of 10% in comparison to the MERS-CoV virus which
caused over 2,465 cases with a CFR of 34.5% (8). It was predicted that those Coronaviruses
would cause future disease outbreaks because they evolve within animals, after which get
transmitted to humans via an intermediate host. Previously, the SARS virus intermediates were
the Himalayan Palm Civet and the Racoon Dogs whereas the MERS virus intermediate was
assumed to be the camel (9). It is assumed that bats are the progenitors of SARS-CoV-2 as the
latter shares 96% of its genome with humans (10). The SARS-CoV-2 virus (Severe Acute
Respiratory Syndrome Coronavirus 2) was named by the International Committee on Taxonomy
of Viruses (ICTV) after the SARS virus as its structure resembles that of the SARS virus (7).
SARS-CoV-2 virus is the seventh known coronavirus to infect humans and the third novel
coronavirus to cause a large outbreak worldwide. Compared to the previous family of
coronavirus, SARS-CoV and MERS-CoV, SARS-CoV-2 appears to be more challenging as it
has a higher transmissibility rate. However, COVID-19 appears to have a lower CFR when
compared to SARS and MERS despite the high overall number of mortality from SARS-CoV-2
(8).
Unfortunately, there is no effective treatment to treat the novel coronavirus. However, Food and
Drug Administration (FDA) approved a drug called Remdesivir, which was previously used in
Ebola virus treatment trials. It is effective in decreasing the period of improvement of
coronavirus hospitalized patients from 11 to 14 days. In addition, several vaccines have been
authorized by the FDA to combat the spread of the virus.

1.1.3 Genotype and Phenotype of COVID-19
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Coronaviruses are positive single-stranded RNA and are considered one of the largest genomes
among RNA viruses, ranging in size between 26,000 base pair to 32,000 base pair (11). SARSCoV-2 is a spherical or pleomorphic enveloped shaped virus with a capsid nucleoprotein
comprised of matrix protein (12). SARS-CoV-2 has a series of protein spikes on its surface and
when viewed under a microscope gives a crown shape, resulting in its name corona.
The SARS-CoV-2 genome encodes four structural proteins which are common across all
coronaviruses: the Nucleocapsid protein (N), the Membrane glycoprotein (M), the Spike
glycoprotein (S), and the Envelope protein (E) (13). The SARS-CoV-2 virus uses the SARSCoV receptor Angiotensin Converting Enzyme Receptor 2 (ACE2) to enter the host cells and the
Transmembrane protease, serine 2 (TMPRSS2) for S protein priming (14). The S protein is
responsible for allowing the virus to attach to the membrane of the host cell. It contains a
receptor-binding domain that recognizes a specific receptor, ACE2, expressed in the lungs, the
heart, the kidneys, and the; intestines. The S protein has two functional subunits: the S1 subunit
which binds to the host cellular receptor and the S2 subunit which enables the fusion of the viral
and cellular membranes. The M protein, which defines the shape of the viral envelop, is the most
abundant protein on the viral surface, spanning the membrane bilayer three times (12). It is also
the central organizer for the coronavirus assembly and interacts with the other structural proteins.
The envelope protein, which is the smallest structural protein, is localized at the endoplasmic
reticulum and the Golgi apparatus (15). It is important for the assembly and release of virus from
host cells and during viral replication. Together the M and E proteins play a critical role in
turning the host cell into machinery for the virus to replicate and synthesize new viruses. Beneath
the surface proteins lie the viral envelope and the virus outer layer. The capsid, the protein shell
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that encloses the genetic material of the virus, is located underneath the viral envelope. Inside
this capsid, the N protein binds to the single-strand RNA, allowing its replication.
1.2 Clinical Manifestation
The symptoms of COVID-19 vary from one individual to another, depending on several factors
including immune system efficiency, age of the patient, respiratory disorders, and presence of
comorbidities. The incubation period of the disease is approximately 5.2 days (1). At the onset of
COVID-19, a number of symptoms can appear, cough, fever, and fatigue being the most
common of these symptoms. In some cases symptoms can include headache, diarrhea, sputum
production, hemoptysis, and dyspnea (1).
The diagnosis of COVID-19 and the assessment of disease severity depends on three main
methods which are PCR, CT scans, and lab tests. Lab tests for ferritin, d-dimer, C-reactive
protein (CRP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine,
total leukocyte count (TLC), and hemoglobin in blood are crucial biomarkers for the diagnosis of
the disease (16). In addition, these biomarkers are used to determine the onset, progression,
severity, need for hospitalization and intensive care unit (ICU) admission, and disease outcome
(16). A study carried out by Keddie et al illustrated that CRP, lactate dehydrogenase (LDH),
Interleukin 10 (IL-10), and Tumor necrosis factor α (TNF-α) are biomarkers that indicate
COVID-19 severity, presence of Acute respiratory distress syndrome (ARDS), oxygen, and
intensive care support requirements (17). The most important biological biomarker in assessing
COVID-19 patients is the CRP, as it is a reliable marker for showing inflammation in the body
and disease progression. In severe patients an elevated level of CRP indicates elevated levels of
inflammatory cytokines, resulting in lung tissue damage due to cytokine storm (18).
Hyperimmune response presented in cytokine storm against the virus, as in elevated interleukin17

Introduction

6 (IL-6), is an indicator of disease severity. Several studies have indicated that elevated levels of
IL-6 as an inflammatory response by the immune system leads to the block of gas exchange and
collapse of the lungs(19). D-dimer is a biomarker released due to the lysis of fibrin, and elevated
levels indicate coagulopathies in COVID-19 patients (20). According to health practitioners,
levels of d-dimer and thrombocytopenia are elevated in patients with severe COVID-19, which
indicates a state of hypercoagulation resulting in severe illness and mortality among COVID-19
patients(21). In COVID-19, LDH is a marker for cardiac and pulmonary damage and decreased
oxygenation leading to ARDS which influences the course of the disease(21). Considering all
previously mentioned biomarkers and identifying a correlation between case severity and
biomarkers release presents a convenient and insightful method for medical practitioners. These
biomarkers might help medical staff base their diagnosis, predicting the course of the disease by
monitoring the physiological conditions and response.

1.3 The Pathogenic Mechanisms of COVID-19
The virus mechanism of replication starts by inserting its RNA into cells by means of hijacking
the cellular machinery in order to replicate. The SARS-CoV2 virus binds via S protein to the
ACE2 receptor, after which it releases single-stranded RNA into the cytoplasm, using the host
cells ribosomes to translate mRNA into proteins (12). The endoplasmic reticulum transfers this
structural protein into the Golgi apparatus where it will be nicely packaged up with the positive
RNA strand formed to form a new virus (22). New virions are then assembled by fusing to the
plasma membranes and released as vesicles via the cellular exocytic secretory processes to
release the virus (23). This results in stress placed on our cells by the virus leading to cell deaths.
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Figure 2. Pathogenic Mechanism of COVID-19. Covid-19 spreads via respiratory droplets and the
virus gets into the respiratory system and attacks the alveoli. (i)The spike protein of the virus attaches to
the angiotensin converting enzyme type-2, allowing virus entry. (ii) Once inside the cell the virus
releases single-stranded RNA into the cytoplasm and uses the host cells ribosomes to translate mRNA
into proteins. (iii) Single stranded RNA is translated into specific protein molecules called polyproteins.
(iv) Proteinases proteolytically cleave the polyproteins into different viral components that make the
nucleocapsid enzymes and spike proteins. (v) Single stranded RNA RNA-dependent RNA polymerase to
make more RNA copies. (vi) +ssRNA copies combine with the nucleocapsid and spike proteins
enzymes. (vii) Virus replicates resulting into lung damage.

1.4 Immunogenicity of COVID-19
SARS-CoV-2 infection acts by activating both the adaptive and innate immune responses as seen
in figure 3 below. Pro-inflammatory cytokines when produced at high levels result in shock and
tissue damage in the heart, kidney, and liver in addition to respiratory failure or multiple organ
failure (24). While the virus is self-replicating in the alveolar cells, it initiates an inflammatory
response. This leads to massive infiltration of neutrophils and macrophages, diffuse of alveolar
damage, diffuse thickening of the alveolar wall leading to a buildup of mucus, and hyperplasia of
the cells within the airways (24). Interferons, cytokines, and intracellular components are
19
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released in response to the inflammatory response. Interferons produce antiviral agents to induce
protection against viruses infecting other cells. Alveolar macrophages detect cell injury and
respond to cytokines released by injured alveolar cells, secreting proinflammatory cytokines,
such as IL-1β, TNFα, and IL-6, and chemokines (25). IL-1β, TNFα are proinflammatory
cytokines that increase vascular permeability and expression of adhesion molecules, allowing the
recruitment of more immune cells including neutrophils and monocytes which bind to these
adhesion molecules and enter the site of injury (26). The increase of vascular permeability causes
interstitial edema, after which it leaks into the alveoli causing pulmonary edema, resulting in
dyspnea, hypoxemia, and low oxygen levels in the blood. Other inflammatory mediators such as
leukotrienes (LTs) and prostaglandins (PGs) are also released because of alveolar damage, and
their function is to signal molecules that play roles in inflammatory and immune responses (27).
Alveolar macrophages can also detect the virus using its special receptors such as toll-like
receptors (TLRs) and CD14. CD14 entails transmembrane receptors to initiate a stimulusspecific activation process, while TLRs are accountable for fast recognition and response to
pathogens (26). Alveolar macrophages engulf the virus through phagocytosis, process it, and
present it on its surface for degradation. In conclusion, it is essential to explore and understand
the immunogenicity of COVID-19 to develop treatment strategies and effective vaccines.
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Figure 3. Immunogenicity of COVID-19. The process of immunogenicity commences by corona
virus infecting the lung cells. The damaged lung cells release specific inflammatory mediators which
stimulates the macrophage to release specific cytokines. IL-1, IL-6, and tumor necrotic factor alpha are
released into the bloodstream. Endothelial cells undergo dilation which increases capillary permeability.
The plasma starts flowing out and leaking into the interstitial spaces and potentially into the alveoli
resulting in fluid accumulation outside the alveoli. Some fluid will enter the alveoli resulting in alveolar
edema that will drown out the surfactant and as a result the surface tension of the alveoli will increase
resulting in alveolar collapse and decrease in gas exchange. This leads to hypoxemia and increase the
work of breathing and eventually result in acute respiratory distress syndrome.

1.5 Treatment/Management against COVID-19

1.5.1 CoV Fusion/Entry Inhibitors
A vital step of the virus lifecycle that can be used as a target for the therapy of CoV is the viral
entry mechanism. The main function of the S1 subunit is to bind to the host cell surface receptor
angiotensin-converting enzyme 2 ACE2 (29). The function of the S2 subunit is to facilitate virus
fusion and entry into the host cell, resulting in the interaction of the heptad repeat 1 (HR1) and
heptad repeat 2 (HR2) to form a six-helical bundle (6-HB), leading to the proximity of the viral
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and cellular membranes for fusion (30). This mechanism suggests a potential therapeutic drug
that contains antigens derived from the spike protein. Bamlanivimab from Eli Lily and REGNCOV2 (casirivimab and imdevimab) are COVID-19 treatments which develops monoclonal
antibodies, binding to the coronavirus spike protein and blocking the interaction with the human
cells (31). Another target is the transmembrane protein serine 2 TMPRSS2, which is essential for
the entry and spread of the coronavirus. Camostat mesylate is a clinically proven antiviral drug
against COVID-19, which acts by inhibiting the activity of TMPRSS2 (14). Another potential
drug target could be between the interaction sites of ACE2 and spike protein. Hesperidin, a
natural flavonoid, is predicted to bind with the binding interface of the spike receptor-binding
domain (RBD) and human ACE2. This results in the re-folding of the spike, thereby inhibiting
the viral infection process (32).

1.5.2 CoV -RBD-Specific Neutralizing Antibodies
The binding of spike protein to ACE2 downregulates the receptor and thereby contributes to lung
injury. This suggests that the delivery of an excessive soluble form of ACE2 may competitively
bind with SARS-CoV-2 and neutralize the virus, rescuing cellular ACE2 which regulates the
renin-angiotensin system to protect the lungs from injury (33). Therefore, the recombinant ACE2
(rACE2) protein may play a role in the protection of ARDS patients, acting as a potential
therapeutic approach in the management of emerging lung diseases (34). Research is conducted
in the development of monoclonal antibodies and/or their functional fragments as assumed
prophylactic or therapeutic agents to prevent or treat COVID-19 (35). After the production of
such antibodies, several steps are required. These include in-vitro testing for neutralizing and/or
cross-neutralizing activity, in vivo evaluation in animal models, and preclinical studies. Clinical
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trials testing is required to determine the safety and efficacy prior to being approved for clinical
application (35).

1.5.3 CoV Replication Inhibitors
A successful replication of the CoV virus leading to infection requires host cellular factors, and
an effective way to explain the mechanisms of viral infection is by systematic identification of
virus-host protein-protein interactions (PPIs) (36). After uncoating, the genomic RNA of
coronavirus acts as an mRNA for translation of the replicase polyprotein 1a (pp1a) and 1ab
(pp1ab), after which the autoproteolytic cleavage of these polyproteins produces several nonstructural proteins including RNA-dependent RNA polymerase, helicase, and nonstructural
protein 3,4, and 6 (37). These nonstructural proteins 3,4 and 6 are responsible for anchoring the
coronavirus replication/transcription complex through recruitment of intracellular endoplasmic
reticulum membrane to form double-membrane vesicles (DMV). Remdesivir and Favipiravir are
antiviral drugs which terminates viral RNA synthesis by inhibiting viral RNA-dependent RNA
polymerase (RdRp), resulting in chain termination (38). Remdesivir has broad-spectrum activity
against members of some virus families and was originally produced to treat the Ebola virus
during the Ebola virus outbreak several years ago; in addition, it was used to treat coronaviruses
such as SARS-CoV and MERS-CoV (39). The clinical impact of Remdesivir on COVID-19
patients is still unidentified, and scientists are working on the outcome of such medication (40).
Ongoing studies suggest that both drugs might be useful in the treatment of early stages of
coronavirus disease.

1.5.4 Repurposing Currently Available Antiviral Medications
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The advantages of repurposing approved drugs include the following: safety profiles,
availability, low cost compared to novel drug, and familiarity to clinicians working with these
drugs (41). Chloroquine, an antiviral drug already on the market, is an antimalarial drug believed
to exert its antiviral activity by increasing the PH of host cell lysosomes, after which it inhibits
the hydrolytic activity of protease enzymes required for processing viral glycoproteins during
infection (42). Other drug combinations include Lopinavir, Ritonavir, Darunavir, and Cobicistat,
all of which belong to a class of drugs known as protease inhibitors originally intended to block
HIV viral replication (42). However, molecular docking studies show that they may also interact
with some proteins that are required for replication of the novel coronavirus.

1.5.5 Passive Antibody Transfer from Convalescent Patient Sera
Convalescent plasma, known as immunoglobulins, is one of the possible therapeutic
interventions for COVID-19. Transfusion of convalescent plasma is a passive antibody therapy
that may avert clinical infection or severity in patients with pathogen exposure (43). The process
begins by collecting blood serum of previously infected patients, after which antibodies are
filtered out and injected into COVID-19 patients. A case study conducted in China, included five
critically ill patients with laboratory-confirmed COVID-19 and acute respiratory distress
syndrome (ARDS). The patients then received transfusions with convalescent plasma IgG and
IgM anti–SARS-CoV-19 antibodies, resulting in an improvement in their clinical status (44). To
conclude, specific IgG antibodies of SARS-CoV-2, when passively transferred by convalescent
plasma, result in neutralizing viral particles and activating the complement system, in turn,
leading to the elimination of the viral load (45). However, there are some risk factors involved
with the transfusion of convalescent plasma such as allergic reactions, transfusion reactions,
infection, and circulatory overload.
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1.5.6 Vaccines
Since the spread of COVID-19 worldwide there have been several attempts to mitigate the effect
of COVID-19. The three front-runner vaccines are the ones made by Pfizer with Bioentch,
Moderna, and Oxford with AstraZeneca. Vaccine efficacy rates differ from one vaccine to the
other. The vaccines from Pfizer/BioNTech and Moderna have high efficacy rates as shown in
table 1.
Table 1. COVID-19 Vaccines Comparison

Timing
COVID-19 Vaccine

Vaccine

Number

Route of
of

developer/manufacturer

platform

of doses

FDA
Efficacy

Administration

Storage
approval

doses
NonRegular
University of

Replicating

Oxford/AstraZeneca

Viral

IM

2

70%

Phase 3

Fridge
Temperature

Vector
0, 28
Moderna/NIAID

RNA

2

-20C up to 6
IM

94.1%

Phase 3

days
0, 28

BioNTech/Fosun
RNA
Pharma/Pfizer

months

2

IM

95%

Phase 3

days

Pfizer and Moderna vaccines have the same mechanism of action; they work as messenger RNA
vaccines to produce antibodies (46). They target the spike proteins on the SARS-Cov2 virus.
There work by taking in a lipid nanoparticle which consists of a phospholipid bilayer that’s
wrapping around the mRNA responsible for the spike protein found on the surface of the SARSCov2 virus (46). This lipid nanoparticle acts as a vehicle or transport mechanism for the virus
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into the host cell. When the nanoparticle fuses with the cell membrane of a host cell it releases
the mRNA into the cell and uses the host ribosomes to make proteins, expressed on the cell
membrane. There are two types of proteins that the cells express. The first protein is called
MHC-II protein and this protein is only found on antigen-presenting cells such as B cells,
macrophages, and dendritic cells (47). The second protein is called MHC-I protein and gets
expressed on all nucleated cells in the body. When the viral spike proteins are expressed on these
complexes it attracts the immune system cells to produce antibodies that are directed against
spike proteins found on the SARS-Cov2 virus. This results in neutralizing the virus and
enhancing the destruction of the virus.
The Oxford/AstraZeneca vaccine also targets the spike protein found on the SARS-Cov2 virus
but from a different perspective. Oxford/AstraZeneca vaccine uses a chimpanzee adenovirus to
house the nucleic acid molecule (46). This will generate an immune response to the protein that
will be expressed by the DNA housed in the chimp adenovirus. This DNA expresses a protein
similar to the spike proteins found on the SARS-CoV2 virus. Once it is injected, the chimp
adenovirus attaches itself to the host cell, releasing its DNA into the host cytoplasm. The DNA
then migrates into the host DNA and uses the host enzymes to convert the DNA into mRNA,
after which it translates the mRNA generated into proteins (46). The proteins will then get
expressed on the cell membrane, MHC-I, and MHC-II complexes and will result in an immune
response to generate antibodies. These antibodies are anti-IgA and IgG and are generated
against the spike proteins found on the SARS-Cov2 viruses and they will destruct them (48). The
reported efficacy for those vaccines ranges from 91 percent to 95 percent. The success of several
vaccines will ensure a limitation against the spread of the virus and as a result reduction in the
number of deaths from the virus.
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Figure 4. Moderna and Pfizer Vaccines. Mechanism of action of mRNA vaccines. The vaccine
consists of a section of mRNA in a lipid nanoparticle injected inside the host cell releasing the mRNA
with the genetic code for the spike proteins on the coronavirus surface.
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Figure 5. Oxford-AstraZeneca vaccine mechanism of action. AstraZeneca uses a chimpanzee
adenovirus which has a DNA that expresses a protein similar to the S-peptide of the virus. Upon
administration, the virus releases its DNA into the host cytoplasm. The virus DNA migrates into the
nucleus of the host cell and uses host cell enzymes to convert the DNA into mRNA. The cell’s
ribosomes translate the mRNA to generate spike proteins.

1.6 Different Lockdown Strategies Across Countries

COVID-19 resulted in deaths, weakening the economy, and pressurizing the health system. Due
to the emergence of COVID-19, there were different responses taken across different countries.
To fight the spread of the novel coronavirus, different non-pharmaceutical interventions were
imposed worldwide. This included different social distancing measures such as general
lockdown, movement restrictions, public health measures, and social and economic measures.
There were different policies taken across the most affected countries to reduce the number of
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cases and deaths across countries (the United States, Brazil, Russia, Italy, the United Kingdom,
India, China, and Egypt); as a result, there were different wave patterns in these countries.

China was the first country to detect the novel coronavirus. It recorded the highest number of
deaths between January 2020 and February 2020. China was the first country to impose
lockdown strategies across the city of Wuhan. Wuhan with a population of over 14 million
people imposed a full lockdown period of 76 days (49). Due to the delay of travel restriction
strategies, there was an exponential rise in the number of cases and deaths outside China from
early March 2020. Following China, the most affected countries across the world were Italy, the
United States of America, Brazil, the United Kingdom, India, and Russia (50). The spread of the
virus was increasing rapidly than what was expected with predominance in European countries
and the United States (50).

Italy was the second hotspot after the Wuhan outbreak, recording double the number of deaths in
China. Some scientists suggest that this surge in cases was due to cultural behavior,
demographics, and delay in government regulations to act against the virus following the
detection of the virus (51). While Italy started with a partial lockdown strategy in areas classified
as hotspots, this measure did not lead to a decline in the alarmingly high death toll due to the lack
of restrictions on the mobility of potential carriers. In response to this crisis, an official
nationwide lockdown was imposed on March 10, 2020, as a desperate measure to slow down the
spread of the virus (52).

In a similar vein, India imposed a nationwide lockdown due to the rocketing number of COVID19 cases and deaths ravaging the country. This lockdown did not continue for long, however, as
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the population density in India is high with a large proportion of daily-wage laborers (53).
Another challenge facing India was the lack of a well-established health care system, including
hospitals unequipped with sufficient ventilators and ICU beds. Moreover, India is not a mask
culture-oriented country, resulting in the country’s vulnerability to a second wave.

Egypt showed a similar trend to India regarding the COVID-19 waveform. Lockdown strategies
were not enough to mitigate the spread of the virus. During the peak of the virus hospitals and
health care systems were not well equipped to handle the influx of COVID-19 patients. Thus, it
took time for officials to implement appropriate measures to handle the situation, such as
converting state-owned facilities into temporary hospitals to accommodate the overwhelming
number of patients (54). Furthermore, the testing capacity was not well established in Egypt and
there was an underestimate of confirmed COVID-19 patients, leading to an inaccurate picture of
the situation.
The United Kingdom dealt with the pandemic using a different strategy when compared to the
rest of the world. Boris Johnson, England’s prime minister, suggested implementing herd
immunity, where people become immune to the new virus after being infected with it (55). This,
unfortunately, did not work out as expected and lockdown strategies were implemented after the
number of cases and deaths increased rapidly.
In comparison to other countries, the United States suffered the highest number of confirmed
cases and mortalities worldwide due to inconsistent and ineffective lockdown strategies as well
as public resistance to mask wearing.
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1.7 Risk Factors
It appears that there are emerging risk factors for COVID-19 patients. The risk factors associated
with a fatal course of the disease are increased D-dimer, increased SOFA score, and older age
(56). Patients who have pre-existing hypertension controlled or not controlled, preexisting
diabetes mellitus both type 1 and type 2, hypertension, lung disease, heart disease, liver disease,
kidney disease, immunocompromised have a higher risk of developing the severe or fatal
disease. Cardiovascular disease is one of the highest factors which can increase the mortality rate
in COVID-19 patients by 10.5 % (57). The second highest risk factor is diabetes which increases
by 7.3% in COVID-19 patients (57). The third highest risk factor which contributes to clinical
manifestations of COVID-19 is obesity (57). Those risks increase with age. Elderly people over
the age of 65 are much more likely to have a higher mortality rate from COVID-19 when
compared to younger individuals(58).Patients developing critical COVID-19 disease do so by
developing acute respiratory distress syndrome ARDS, hypotensive shock, and multi-organ
dysfunction. Patients with COVID-19 result in an overactive inflammatory response which
causes tissue damage and systemic effects and this may be due to genetically determined
differences in inherent immune response mechanism (56). Overall COVID-19 progresses
specific risks for older age and those with comorbid conditions.
The most important strategy to manage COVID-19 is to early identify patients with risk factors
to overcome the severity of the disease. Moreover, it is important to collect information about the
patient’s medical history including age, gender, underlying conditions, symptoms, and laboratory
tests to enable the prediction of disease progression in patients, mitigate the spread of COVID19, and lower fatality rates worldwide. Artificial intelligence (AI) and machine learning models
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have been utilized for disease prediction, tracking, diagnosis, and prognosis, hence reducing the
spread of the virus (59).

1.8 Artificial Intelligence
Artificial intelligence (AI) is essential in helping healthcare providers triage and monitor patients
rapidly and accurately. Artificial intelligence models plays a vital role in detecting COVID-19
cases, predicting transmission between people through networks that enable the detection of in
contact cases. For example, through the Wi-Fi networks, which help in limiting the spread of the
infection as it notifies people who were in contact with diagnosed cases(60). Machine learning
(ML), a branch of AI, can be used to learn the data and then build a prediction model that helps
us in identifying relations and patterns associated with COVID-19 outcomes. Machine learning
is engaging in three major roles: the infection risk, the risk of an individual to develop COVID19, and severity risk (61). The risk of an individual developing severe COVID-19 symptoms or
complications leading to hospitalization or ICU admission, together with the effectiveness of a
certain treatment protocol can be predicted through established models, which are fed with
existing clinical data entries and their outcome points. Thus, it is strongly believed that machine
learning tools hold great potential as an efficient predictive tool that would help health care
practitioners predict and manage cases of CoV-19 patients based on their vulnerability to the
associated risk factors.
Random Forest Algorithm is a machine learning technique that is used in regression and
classification. It contains trees, representing decision trees. The decision tree is a flowchart-like
structure where each internal node denotes a test, each branch represents an outcome of a test
and each leaf or terminal node holds a class label (62). The topmost node in a tree is the root
node. In decision analysis, a decision tree can be used to represent decisions and decision32
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making visually and explicitly. Decision trees implicitly perform variable screening or feature
selection. The advantage of decision trees is that they can handle both numerical and categorical
data (62). In addition, non-linear relationships between parameters do not affect the tree
performance.

1.9 Objectives
The first aim of this study is to analyze the effectiveness of lockdown measures across different
countries which were mostly affected by the pandemic. To achieve this, the study will analyze
the number of COVID-19 cases, deaths, and recovered in the following countries: the United
States, China, Brazil, Italy, India, Russia, the United Kingdom, and Egypt. This study will also
carry out statistical analysis to examine the effect of lockdown on the growth rate in several
cases and deaths across countries that imposed nationwide lockdown.
This study also aims to analyze COVID-19 patients in Egypt during the lockdown period and
provide a description of the risk factors and clinical outcomes associated with the severity of
COVID-19. To achieve this, I will use a machine learning model to predict disease severity and
take the required preventive measures. I will build a Random Forest model that predicts patients’
severity based on the most important risk factors fed in the model and the most important clinical
outcomes according to the severity of the disease. I will classify the different factors which
affects the severity of COVID-19 by using different decision trees. This will be performed by
splitting our data into different decision nodes based on our factor’s value. I will be provided
with medical history and clinical laboratory data, and it will be ingested into our algorithm to
predict a score of patients who might develop a severe case. The predictions will be based on
learned patterns from past data. This will hopefully help us to detect severe cases, lower
emergency cases, and help doctors make decisions and resource allocation as there is limited
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equipment across the world. I will apply different machine learning models on the Egyptian
dataset to predict the severity of the infection of the virus based on the different parameters
collected. Our model will allow healthcare professionals to strategically provide the optimal care
for COVID-19 patients and help in deciding the most effective preventive strategies.
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Chapter 2: Materials & Methods
2.1 Study Subjects and Design
The programming tool I used in the analysis of the datasets was R Studio. I analyzed the data of
COVID-19 cases, deaths, recovery in eight countries across different continents through graphs
and it was suitable as there was a variety of packages installed to help in the visualizing of data.
The libraries used in R studio to analyze the data were: tidyr, dplyr, tmap, deSolve.
The 2019 novel coronavirus data owid-covid-data.csv was imported from GitHub:
https://github.com/owid/COVID-19-data/tree/master/public/data which is operated by the John
Hopkins University. The data includes the number of confirmed, deaths, and recovered cases. I
started by cleaning our data using the package tidyr. The ggplot2 package was used to analyze
the data in graphs and charts. The vertical axis of the charts was in logarithmic scales. I used a
log scale to maintain the same distance on the scale so that I can analyze the rate of pandemics
across different countries. Moreover, the exponential growth on the log scale gives a more
realistic view of the real situation of the pandemic. The study employed the Tmap package in
order to visualize real-time world maps with spatial data global distribution of the pandemic.
The merged COVID-19 Data with Governmental Interventions Data found on the shiny app
created by Joachim Gassen was used to visualize the governmental intervention measures and
their impact on the infection rate and deaths rate in several selected countries (63).
Several curated datasets were included in this study, and the data were retrieved from January 1,
2020, till December 21, 2020. The change in confirmed, deaths, and recovered cases were
analyzed across eight different countries from different continents were the number of cases
where the highest. China was included as it was the first country where COVID-19 was detected.
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Egypt was included as the research was comparing the effect of COVID-19 in Egypt to the other
most affected countries across the world.

2.2 Selection of Datasets
Three different from different sources were used. The first dataset is from Our World in Data
and testing (64). The second dataset is provided by Johns Hopkins University available in the
GitHub repository (65). This dataset is updated on a daily level. The data is available in CSV,
XLSX, and JSON formats making it easy for researchers and data analysts to analyze the data.
This dataset includes information on confirmed cases, deaths, recovered, hospitalizations, and
testing, as well as other variables of the potential interest of COVID-19. The third dataset was
the government measures dataset provided by the Assessment Capacities Project (ACAPS) (66).

2.3 Data Screening and Visualization
Datasets were visualized in terms of tables, bar charts, line graphs, and maps using R-studio and
excel. I analyzed collected data from eight different countries (the United States, Brazil, Russia,
Italy, the United Kingdom, India, China, and Egypt). I compared the number of confirmed cases,
recovered, and deaths across the different countries. I also provided a world map representation
of the different countries with confirmed, recovered and deaths reported on 30 November 2020. I
analyzed non-pharmaceutical interventions such as general lockdown and their effect on the
number of cases and deaths between different countries.

2.4 Growth Factor Model of Effect of Lockdown Strategies
I calculated the growth rate according to the model defined by Meo, S.A., Abukhalaf, A.A.,
Alomar, A.A. et al. which states that the growth rate is calculated by the number of cases/deaths
on a given day divided by the number of cases/deaths on a preceding day (67). An increase in the
number of cases/deaths is defined by a growth rate greater than 1.0, while a decline in the
number of cases/deaths is defined by a growth rate equal to or below 1.0 (67). I recorded the
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number of cases and deaths in 6 different countries before, during, and after 15 days of
lockdown. I calculated the mean value and SEM of the number of cases and deaths in 6 different
countries before, during, and after 15 days of lockdown. I then analyzed the level of significance
of the lockdown on the growth rate of the number of cases and deaths. ANOVA test was carried
out and results were considered significant when p-value < 0.05.

2.5 Study Design: Clinical Feature Extraction of COVID-19 Egyptian Patients
I used a provided dataset from 2,813 patients treated at six different centers in Egypt from the
period of May 1, 2020, to July 31, 2020. I analyzed the COVID-19 dataset of cases admitted to
hospitals affiliated with the General Organization for Teaching Hospitals and Institutes
(GOTHI). I classified the severity of the disease based on the oxygen saturation and GCS
(Glasgow Coma Scale), and Erythrocyte sedimentation rate (ESR). Patients were classified into 3
categories (mild, moderate, severe). Cases were confirmed through RT-PCR. The patient’s
medical history was provided in the dataset. The dataset included blood tests carried out for all
patients to perform laboratory analysis. Patients with no PCR confirmation of SARS-CoV-2
were excluded from the study.

2.6 Study Design of Egyptian COVID-19 Patients
Demographic factors were registered in patients in terms of age and sex. Cases involved in this
study were subcategorized into 8 groups starting from 20 years of age till 90 years of age with a
10-year incremental increase across the groups. Sixty years is chosen as a cut-off point for the
main analyses because most severe patients fell into this age group. Patients’ data were collected
at the time of admission and during the disease. This included the sex and smoking history of
patients. Medical history included 9 preexisting comorbidities such as renal disease, cardiac
disease, HCV, hypertension, asthma, diabetes, thyroid disease, and liver cirrhosis.
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Moreover, the dataset included collected laboratory blood tests. These tests included: ferritin, ddimer, C-reactive protein (CRP), partial thromboplastin time (PTT), neutrophil-to-lymphocyte
ratio (NLR), albumin, alanine aminotransferase (ALT), creatinine, total leukocyte count (TLC),
aspartate aminotransferase (AST), bilirubin, potassium, and hemoglobin.
I developed a machine learning model through the identification of risk factors in patients and
key clinical outcomes in order to predict the severity of the disease in patients prior to
implementing the required measures.

2.7 Ethical Committee Approval
This study was approved by the research ethics committee of the Ministry of Health and
Population (number 17-2020/8, June 21, 2020) and the research ethics committee of the Faculty
of Medicine at Cairo University (number N-37-2020, May 14, 2020). Patients were informed by
the data shared and written consents were signed by patients participating in this study. To
ensure confidentiality, patients ' data (e.g., name, ID) were excluded from the collected data of
this study to protect the privacy of the data.

2.8 Random Forest: Data Mining on Multimodal Features
The flow chart for the thesis design is shown in figure 6 below. Patient’s data were provided for
2,813 COVID-19 patients admitted to hospitals affiliated to GOTHI from May 1, 2020, to July
31, 2020. The provided data was then cleaned to remove missing fields, duplicated fields, and
outliers. Random forest classifier was used to divide the dataset into 4 subsets: Demographic,
epidemiological, comorbidities, and clinical analysis of Covid-19. The dataset was fed into a
random forest model to predict the risk factors of COVID-19 patients. Bootstrap aggregation was
used to randomly collect the clinical data for a total of 500 times. The split criterion was the Gini
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index. All data were processed using R.

2,813 COVID-19 patients admitted to GOTHI from
May 1, 2020, to July 31, 2020.
Demographic, epidemiological, comorbidities, and
clinical analysis of COVID-19 patients

Identifying prediction ability of RF model and spotting
high risk clinical indicators

Figure 6. Flowchart for the research design. A total of 2,813 with confirmed COVID-19 Egyptian
patients admitted to GOTHI between 1 May and 31 July 2020 were included in the Random Forest
model. Demographic, epidemiological, comorbidities, and clinical data were collected to identify severity
of COVID-19.

Chapter 3: Results and Discussion
3.1 Graphical Representation of confirmed, deaths, and recovered COVID-19 cases
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Figure 7. Global Cases Worldwide COVID-19. Daily cases resulting from COVID19. Worldwide crude data were transformed to log10 to observe the change in the trend
of COVID-19 global cases. Data were collected from the beginning of January 2020 till
the end of December 2020. The data is demonstrated through stacking bar categorized
into four main groups: confirmed (Red), cumulative confirmed (Green), deaths (Blue),
and recovered (Purple).

The global cases are shown to increase dramatically from the end of January till the end of
September, a sharp decrease in the global cases is shown (Figure 7) in the duration between
September till October. The overall trend in the number of cases indicates an increase from
October till early December 2020.
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Figure 8. Confirmed cases by country COVID-19. Daily confirmed cases in 8 countries (Brazil,
China, Egypt, India, Italy, Russia, United Kingdom, US). Confirmed cases by country crude data
were transformed to log10 to observe the change in the trend of COVID-19 across different countries.

The confirmed cases are shown to increase rapidly at the beginning, each country with a different
rate, and each country hits a plateau at different timings (Figure 8)1. China starts with an earlier
number of cases when compared to the other countries and hits a plateau for a longer period
(Figure 8). Some countries such as Brazil, India, Russia, and the US show an increase in the
number of cases after the plateau (Figure 8). There is a slight decrease in the number of cases for
a short period after the plateau phase in Italy and the United Kingdom (Figure 8). The US shows

1

Data were collected from day 0 which is 1-1-2020 till day 355 which is 20-12-2020
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the highest increase in the number of cases. The overall trend in the number of confirmed cases
across different countries has been increasing.
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Figure 9. Death cases by country COVID-19. Daily deaths cases in 8 countries (Brazil, China, Egypt, India, Italy,
Russia, United Kingdom, US). Confirmed deaths by country crude data were transformed to log10 to

observe the change in the trend of COVID-19 across different countries
The deaths cases are shown to increase rapidly at the beginning, each country with a different
rate, and each country hits a plateau at different timings (Figure 9)2. China starts with an earlier
and higher number of deaths when compared to the other countries and hits a plateau phase for a
longer period without showing any increase in the number of deaths (Figure 9). Italy shows a
high number of deaths after China and the number of deaths increases rapidly after then (Figure
9). The US then follows Italy in the high number of deaths and increases rapidly until today
(Figure 9). Some countries such as Russia, Italy, and the United Kingdom are showing a slight
increase in the number of deaths after being in the plateau phase (Figure 9). Egypt shows a slight

2

Data were collected from day 0 which is 1-1-2020 till day 355 which is 20-12-2020
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increase in the number of deaths when compared with the other countries (Figure 9). The overall
trend in the number of deaths across different countries has been increasing.

Figure 10. Recovered cases by country COVID-19. Daily recovered cases in 8
countries (Brazil, China, Egypt, India, Italy, Russia, United Kingdom, US). Recovered
deaths by country crude data were transformed to log10 to observe the change in the
trend of COVID-19 across different countries

Recovered cases increase across each country at a different rate (Figure 10)3. China started with
the first cases of recovery and then showed a steady recovery rate before all the other countries
(Figure 10). Italy then followed China and showed a rapid increase in the recovery rate and then
a steady recovery rate and then an increase in recovery rate (Figure 10). At some point, the US

3

Data were collected from day 0 which is 1-1-2020 till day 355 which is 20-12-2020
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showed the highest recovery cases, but then showed a steady increase in the recovery cases.
India started to show recovery cases later than the other countries but showed the highest
increase in recovery cases for that duration (Figure 10). While the United Kingdom showed a
noticeable increase in the recovery cases at the start of the pandemic, the recovery cases
increased at a very low rate when compared to other countries, illustrating the lowest number of
recovered cases (Fig 10).
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Figure 11. Confirmed Cases Worldwide COVID-19. Confirmed cases worldwide data were
transformed to log10 to observe changes in COVID-19 trends across all countries.

The data is represented through a map categorized into five different shades of blue. The lighter
shade of blue shows a high degree of severity while the darkest shade of blue shows a low degree
of severity. It should be mentioned that this color categorization applies to all three maps
included in the study. The most affected countries are Brazil and India (Figure 11)4. Russia, the
United Kingdom, France, Italy, and Turkey show an intermediate degree of severity (Figure 11).
Most countries in Africa and Australia show a low degree of severity as indicated by the darkest
shade of blue (Figure 11).

4

Data were collected on 30-Nov-20.
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Figure 12. Death Cases Worldwide COVID-19. Deaths cases worldwide data were transformed to
log10 to observe the change in the trend of COVID-19 across the world.

Brazil shows the highest number of deaths worldwide (Figure 12)5. Following Brazil are Mexico
and India which also show a high number of deaths (Figure 12). Russia, Iran, Italy, France, the
United Kingdom, Germany has an intermediate number of deaths (Figure 12). Most countries in
Africa and Australia have the lowest number of deaths (Figure 12).

5

Data were collected on 30-Nov-20.
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Figure 13. Recovered Cases Worldwide COVID-19. Recovered cases worldwide data were
transformed to log10 to observe the change in the trend of COVID-19 across the world

Brazil and India show the highest number of recovery rates (Figure 13)6. Following Brazil and
India is Russia which shows an intermediate number of recovered cases (Figure 13). Most
countries then follow approximately the same number of recovered cases (Figure 13).

6

Data were collected on 30-Nov-20.
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Figure 14. Reported confirmed cases in Brazil. Data are reported from day 0 which represents the
day after 10,000th reported confirmed case. The y-axis represents the number of reported cases in an
interval of 10,000 cases. The x-axis represents the number of day.

On April 4, 2020, Brazil reported the 10,000 reported cases. Brazil had two general lockdowns
(Figure 14)7. The first general lockdown was on April 8, 2020, and the number of cases was
approximately 16,000 (Figure 14). The second general lockdown was on May 16, 2020, and the
number of cases were approximately 233,000 (Figure 14). However, after the second general
lock down the number of cases increased rapidly (Figure 14). On December 23, 2020, the
number of cases reached 7,300,000 (Figure 14).

7

Data were collected on 04-Apr-20 till 23-Dec-20.
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Figure 15. Reported confirmed cases in China. Data are reported from day 0 which represents the
day after 10,000th reported confirmed case. The y-axis represents the number of reported cases in an
interval of 25,000 cases. The x-axis represents the number of days.

On day February 1, 2020, China reported the 10,000 reported cases. China had two general
lockdowns (Figure 15)8. The first general lockdown was on May 19, 2020, and the number of
cases were approximately 84,000 (Figure 15). The second general lockdown was on June 19,
2020, and the number of cases were approximately 84,500 (Figure 15). The number of cases
increased at a low rate after the second lockdown.

8

Data were collected on 01-Feb-20 till 28-Oct -20.
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Figure 16. Reported Confirmed Cases in Egypt. Data are reported from day 0 which represents the
day after 5,000th reported confirmed case. The y-axis represents the number of reported cases in an
interval of 50,000 cases. The x-axis represents the number of days, and a total of 270 days are reported.

On April 28, 2020, Egypt reported the 5,000 reported cases. Egypt had one general lockdown
(Figure 16). The first general lockdown was on May 11, 2020, and the number of cases was
approximately 9,000 (Figure 16)9. On December 23, 2020, the number of cases reached 128,000
(Figure 16).

9

Data were collected on 28-Apr -20 till 23-Dec -20.
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Figure 17. Reported Confirmed Cases in India. Data are reported from day 0 which represents
the day after 5,000th reported confirmed case. The y-axis represents the number of reported cases
in an interval of 2,000,000 cases. The x-axis represents the number of days, and a total of 270 days
are reported.

India had five general lockdowns (Figure 17)10. The first general lockdown was on March 16,
2020, and the number of cases were approximately 119 (Figure 17). The second lockdown was
on March 24, 2020, and the number of cases was 536 (Figure 1). The third lockdown was on
May 4, 2020, and the number of cases were 46,000 (Figure 17). The fourth lockdown was on
May 18, 2020, and the number of cases were 100,000 (Figure 17). The fifth lockdown was on
10

Data were collected on 28-Apr -20 till 23-Dec -20.
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June 15, 2020, and the number of cases were 343,000 (Figure 17). After the last lock down the
number of cases kept increasing (Figure 17).

Figure 18. Reported Confirmed Cases in Italy. Daily confirmed cases in Italy from day 0
which is days after 5,000th reported confirmed case. The y-axis represents the number of
reported cases in an interval of 500,000 cases. The x-axis represents the number of days, and a
total of 270 days are reported.

Italy had four general lockdowns (Figure 18)11. The first general lockdown was on March 8,
2020, and the number of cases were approximately 7,000 (Figure 18). The second lockdown was
on March 20, 2020, and the number of cases were 47,000 (Figure 18). The third lockdown was

11

Data were collected on 07-Mar -20 till 02-Dec -20.
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on March 23, 2020, and the number of cases were 64,000 (Figure 18). The fourth lockdown was
on April 11, 2020, and the number of cases were 152,000 (Figure 18). The number of cases after
the last lockdown increased at a slow rate and on September 23, 2020, the number of cases
increased rapidly.

Figure 19. Reported Confirmed Cases in Russia. Daily confirmed cases in Russia from day 0
which is days after 0th reported confirmed case. The y-axis represents the number of reported
cases in an interval of 500,000 cases. The x-axis represents the number of days, and a total of
270 days are reported.
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Figure 20. Reported Confirmed Cases in Russia. Daily confirmed cases in Russia from day 0 which
is days after 20,000th reported confirmed case. The y-axis represents the number of reported cases in an
interval of 500,000 cases. The x-axis represents the number of days, and a total of 270 days are reported.
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Russia had two general lockdowns (Figures 19 and 20)12. The first general lockdown was on
March 28, 2020, and the number of cases were approximately 1,000 (Figure 19). The second
lockdown was on November 16, 2020, and the number of cases were 2,000,000 (Figure 20). The
number of confirmed cases increased rapidly between the first and second lockdown (Figures 19
and 20).

12

Data were collected on 14-Apr-20 till 24-Dec-20.

56

Results

Figure 21. Reported Confirmed Cases in the United Kingdom. Daily confirmed cases in the United
Kingdom from day 0 which is days after 5,000th reported confirmed case. The y-axis represents the
number of reported cases in an interval of 500,000 cases. The x-axis represents the number of days, and
a total of 270 days are reported.

The United Kingdom had four general lockdowns (Figure 21)13. The first general lockdown was
on March 24, 2020, and the number of cases were approximately 5,000 (Figure 21). The second
lockdown was on April 16, 2020, and the number of cases were 112,000 (Figure 21). The third
lockdown was on October 23, 2020 and the number of cases were 834,000 (Figure 21). The
fourth lockdown was on November 6, 2020, and the number of cases were 1,100,000 (Figure

13

Data were collected on 18-Mar-20 till 13-Dec-20.
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21). The number of cases after the second and third lockdown increased rapidly.
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Figure 22. Reported Confirmed Cases in the United States. Daily confirmed cases in
the United States from day 0 which is days after 20,000th reported confirmed case. The yaxis represents the number of reported cases in an interval of 5,000,000 cases. The x-axis
represents the number of days, and a total of 270 days are reported.

The United States did not have any general lockdown (Figure 22)14.

14

Data were collected on 20-Mar-20 till 15-Dec-20.
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3.2 Impact of Lockdown on COVID-19 cases and deaths

Table 2. The mean number of COVID-19 cases before, during and after 15 days of lockdown in six most affected
countries.

Date
Country

Before

Cases15 days

Cases15 days

Date After

before

during

Lockdown

lockdown

lockdown

(mean±SEM)

(mean±SEM)

Date

Cases15 day

During

pafter lockdown

Lockdown Lockdown

value
(mean±SEM)

7.0EBrazil

03-5-20

03-20-20

05-14-20

41.1 ± 17.6

562.3±93.1

3924.4±439.9
08
2.1E-

Egypt

03-9-20

03-24-20

06-27-20

21.1±5.0

72.2±9.7

1209.8±64.4
19
1.6E-

Russia

03-9-20

03-24-20

05-31-20

98.3±21.9

1119.6±175.9

9582.6±230.8
26
8.0E-

India

02-24-20

03-9-20

05-18-20

30.6±8.1

320.8±83.5

10165.4±304.3
27
3.2E-

Italy

03-16-20

03-30-20

05-11-20

487.5±111.3

3770.1±417.1

517.4±42.9
08
3.3E-

UK

03-9-20

03-23-20

04-13-20

664.4±110.0

3756.2±267.4

4689.3±151.9
12

Table 3. The mean number of COVID-19 deaths before, during and after 15 days of lockdown in six most affected
countries.

Country

Date

Date

Date After

Cases15 days
60

Cases15 days

Cases15 day

p-value
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Before

During

Lockdown

Lockdown Lockdown

before

during

after

lockdown

lockdown

lockdown

(mean±SEM)

(mean±SEM)

(mean±SEM)
2.3E-

Brazil

03-5-20

03-20-20

05-14-20

2± 0.57

23.5± 5.28

900.9± 54.6
16
7.7E-

Egypt

03-9-20

03-24-20

06-27-20

1.2± 0.41

5± 0.65

76.6± 2.5
34
1.5E-

Russia

03-9-20

03-24-20

05-31-20

0.75±0.35

9.3±1.73

114.5±5.64
24
1.3E-

India

02-24-20

03-9-20

05-18-20

0.92±0.28

9.3±2.65

289±14.8
25
1.7E-

Italy

03-16-20

03-30-20

05-11-20

30.6±9.84

423.8±55.4

104.4±9.36
10
4.5E-

UK

03-9-20

03-23-20

04-13-20

24.2±5.9

479.4±71.3

803.0±72.4
11
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Figure 23. Growth factor of COVID-19 cases 15 days before, during, and after lockdown. The yaxis represents the growth factor of cases and the x-axis represent the lockdown periods.
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Figure 24. Growth factor of COVID-19 deaths 15 days before, during, and after lockdown. The
y-axis represents the growth factor of deaths and the x-axis represent the lockdown periods.

Tables 2 and 3 shows the impact of lockdown on the number of cases and deaths across 6
different countries. The lockdown is expressed at 3 time periods: Before the lockdown, during
the lockdown, and after the lockdown. Each period constitutes 15 days. There was no impact of
the lockdown on the mean value of the cases and deaths across the 6 countries. This was shown
by an increase in the number of cases and deaths after the lockdown (Tables 2 and 3). However,
Italy showed a lower mean in the number of cases and deaths after the lockdown. Figures 23 and
24 shows the growth rate in the number of cases and deaths across the 6 countries. Egypt showed
a spike in the number of cases before the lockdown period (Figure 23). The UK showed a spike
in the number of deaths before the lockdown period (Figure 24). There was a decline in the
63

Results

growth rate of the daily number of cases and deaths after the lockdown period in the 6 countries
(Figures 23 and 24).
3.3 Classification of COVID-19 case severity based on various factors (demographic,
epidemiological, comorbidities and the clinical outcome)
I was provided with a curated dataset of 2,813 patients who were admitted to hospitals affiliated
with the GOTHI between the period May 1, 2020, to July 31, 2020. Patient severity was
classified based on the criteria shown in (Table 4). Demographic data included gender and age
and the average age of the patients was 50.8 (Table 5). The incidence of COVID-19 in female
patients was significantly higher than in males, with a p-value of 0.000191. The most common
symptoms were fever and sore throat. Common comorbidities linked to the severity of COVID19 were renal impairment and cardiac disease (Figure 25). In addition, the most important
clinical outcomes, according to severity, were the oxygen saturation and Glasgow Coma Scale
(GCS) (Figure 26).
3.4 Prediction of Case Severity Based on Laboratory Findings
I obtained the Random Forest classification based on the predictions of the combined Decision
trees, where the splitting criteria were the Gini index. The Gini impurity index is a measure of
the diversity of a dataset. The Gini index is higher when the diversity of a dataset is higher. The
clinical outcomes were associated with the severity of COVID-19. Several tests were performed
to measure the spectrum of the disease and categorize patients from mild to critical cases.
Laboratory findings were provided to me and they included several blood tests.
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Of the included 2,813 patients, patients were categorized into mild, moderate, and severe cases
based on case severity classification which includes diagnosis, clinical symptoms, laboratory,
and radiography findings (Table 4).
Table 4. Case severity classification

a. Mild

b. Moderate

c. Severe

RT-PCR confirmed case + RT-PCR confirmed case RT-PCR confirmed case
one of the following
+ one of the following
+ one of the following
1. Show one or more

of the following
symptoms: fever,
cough, sore throat,
malaise, headache,
muscle pain,
nausea, vomiting,
diarrhea, loss of
taste and smell.
2. SpO2 ≥97%

1. Show symptoms
of pneumonia

1. Respiratory
distress requiring
mechanical
ventilation

2. SpO2 ≥94%

2. SpO2 <94%

3. Respiratory

3. Respiratory rate >30
breaths/min

rate﹤30
breaths/min

4. ICU Admission
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Two variables fell under demographic features: Age and gender. While epidemiological features
included three variables: contact with confirmed or suspected cases, and smoking. The number
of asymptomatic patients was 283 (10%) out of 2813 patients. Our data also included
comorbidities such as renal disease, malignancy, HCV, hypertension, asthma, diabetes, thyroid
disease, and cirrhosis.

Table 5. Demographic features, epidemiological features, and comorbidities

Category

Features

Definition

The age of the patient calculated from the date of
1- Age
birth

Demographic
Features

Patient’s sex (Male/Female)

2- Gender

3- Contact with
Patient coming in contact with a confirmed or
Confirmed or
suspected case in the last 4 days
Suspected cases
Epidemiological
4- Smoking

Whether patients never smoked or were former
smokers or were current smokers
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Hospitalization admission with a diagnosis of
cardiac diseases (angina, chronic ischemic heart
5- Cardiac Disease

disease, or myocardial infarction) in the past five
years.

Hospital admission with a diagnosis of chronic
kidney diseases or emergency department visit for a
6- Renal Disease

diagnosis of chronic kidney diseases within the last
five years.

Comorbidities

Hospital admission with a diagnosis of cancerbased on at least one diagnosis. All malignant
7- Malignancy

cancers (Breast, Colon, Gastric, Leukemia,
Oesophagus, Ovarian Renal) were diagnosed within
the last five years.

8- HCV

Hospital admission with an HCV diagnosis OR or
two physician claims of HCV diagnosis in two
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years.

Hospital admission with a diagnosis of hypertension
9- Hypertension

or two physician claims for hypertension within two
years.

Hospital admission with a diagnosis of asthma or
two physician claims of asthma diagnosis in two
10- Asthma

years.

Hospital admission with a diagnosis of diabetes or
two physician claims for diabetes or one
11- Diabetes
prescription claim for diabetes medications within 1
year.

Hospital admission with a diagnosis of thyroid
12- Thyroid

disease based on at least one diagnosis. Thyroid

Disease

disease includes (Hyperthyroidism and
Hypothyroidism) diagnosed within 1 year.
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Hospital admission with a cirrhosis diagnosis OR
13- Liver Cirrhosis

patients who have at least one outpatient visit and
one hospitalization

The total number of female cases were higher than the total number of male cases by 1.6%
(Table 6). There were more severe cases in females when compared to the number of male
severe cases (Table 6). There was a significance between the disease severity and gender of the
patient as the p-value was 0.000191 < 0.05.

Table 6. Correlation between sex and severity of COVID-19.

All patients

mild

moderate

normal

severe

Grand Total

F

5

1229

4

210

1448

M

7

1176

2

179

1364

Grand Total

12

2405

6

389

2812

P -value

0.000191

There was a strong correlation between the severity of COVID-19 and age (Figure 25). The most
affected age group was 50 years and followed by the age group 60 years. There was also a strong
correlation between direct contact with COVID-19 patients and the severity of the disease.

69

Results

Comorbidities affect the severity of COVID-19 with renal disease and cardiac disease showing
the most correlation to the severity of the course of the disease (Figure 25A).

Figure 25. Using Random Forest model for identification of comorbidities related to COVID-19
severity in Egyptian patients. Ranking of comorbidities using A) Mean Decrease Accuracy B) Mean
Decrease Gini

Age was divided into 8 groups with an interval of 10 years and the patient’s age fell between 20
years and 90 years. I found that the most affected age group was between 50-59 years with a
total number of 683 patients (Table 7). The most severe cases of COVID-19 were found to be in
the age group 60-69 with 105 severe COVID-19 cases (Table 7).

Table 7. Age group of patients based on the grade of disease severity.

Age

Grand
20-29

30-39

40-49

50-59

60-69

70-79

80-89

90+
Total

Disease
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Severity
moderate

98

268

476

581

532

330

73

3

2361

severe

9

27

75

100

105

56

14

1

387

mild

1

3

3

0

3

2

0

0

12

normal

1

0

0

2

1

2

0

0

6

109

298

554

683

641

390

87

4

2766

Grand
Total

In Figure 26A the most important clinical outcomes were oxygen saturation, Glasgow coma
scale (GCS), erythrocyte sedimentation rate (ESR), ferritin, d-dimer, and C-reactive protein
(CRP). Out of the top five variables, oxygen saturation showed the highest correlation between
the severity of COVID-19 and clinical outcome Figure 26A, following that was the Glasgow
Coma Scale (GCS) and Erythrocyte sedimentation rate (ESR).
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Figure 26. Using Random Forest model for identification of clinical characteristics related to
COVID-19 severity in Egyptian patients. Ranking of clinical characteristics using A) Mean Decrease
Accuracy B) Mean Decrease Gini

Figure 27 shows the relation between ferritin levels and disease severity in COVID-19 patients.
There was a significant difference between severe cases and mild cases in ferritin levels. The
ferritin levels were the highest in severe cases with a mean ferritin level of 1062 ng/mL while in
mild cases the mean ferritin level was 312 ng/mL. This indicated that ferritin levels did have a
significant correlation with disease severity in COVID-19 patients.
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Figure 27. Box plot chart showing the correlation between Ferritin and disease severity.
Comparison of Ferritin levels in mild, moderate, and severe groups might be relevant to
explain disease severity in COVID-19 patients (p = 2.9E-13). Box plots indicate
median
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Figure 28 shows the relation between D-dimer levels and disease severity in COVID-19 patients.
The levels of D-dimer increased significantly with increasing disease severity of COVID-19.
When compared between severe and mild cases, D-dimer levels were higher in severe cases than
in mild cases. The mean level of D-dimer levels in mild, moderate, and severe was 0.43 μg/ml,
1.2 μg/ml, and 1.5 μg/ml respectively. This indicated that d-dimer levels did have a significant
correlation with disease severity in COVID-19 patients.

Figure 28. Box plot chart showing the correlation between D-dimer and disease
severity. Comparison of D-dimer levels in mild, moderate, and severe groups might be
relevant to explain disease severity in COVID-19 patients (p = 1.47E-16). Box plots
indicate median
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4. Discussion
The outbreak of COVID-19 started in Wuhan, China, and spread worldwide. Several countries
were severely affected by the new pandemic and had a high number of cases and deaths.
Consequently, it is vital to analyze real-world-time-series datasets to visualize the state of the
virus and take protective measures against it. This thesis reports the cases of COVID-19 across
the most affected countries by visualizing three things: the number of confirmed cases, deaths,
and recovered cases during 2020. Several factors are taken into consideration when comparing
the number of confirmed cases and deaths such as testing capacity, population and distribution,
availability and accessibility of healthcare facilities, and availability of hospital beds (68).
The number of cases has been increasing globally since the start of the pandemic. Figure 7
illustrates the increase in the number of cumulative confirmed cases on daily basis across the
world. Early in January 2020, the number of cases increased rapidly in China (Figure 8), but it
was contained in a short period as China took effective actions early on. This was due to the
identification of the new virus. China did not have a national lockdown; however, Wuhan and
other nearby affected cities took national emergency measures such as suspending all forms of
activities and implementing travel restriction policies (69). The virus then began spreading to
other countries nearby China. The number of cases had plateaued worldwide until March 2020.
In mid-March, the number of cases had been increasing rapidly in some countries such as Italy,
showing a high death rate at the beginning of the pandemic (Figure 8 and Figure 9). This early
increase in deaths was due to the high age distribution in the Italian population and the
unpreparedness of the Italian government to face this pandemic with the limited hospital
resources and testing capacity (70). By the end of March, there was exponential growth in the
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number of cases and as a result, protective measures were taken. Unfortunately, the protective
measures were not effective and other countries became the hotspot of the virus, resulting in an
accelerated number of deaths. The risk of COVID-19 was increasing rapidly, and governments
had to impose protective measures to combat the effects of the virus. Governments across
different countries took several protective measures to minimize the spread of COVID-19, such
as general lockdown, public health interventions, and airport closures (71).
The United States had the highest number of confirmed cases when compared to the other
countries (Figure 8). The United States showed the highest number of deaths worldwide because
of several factors. First, the United States did not impose a nation-wide lockdown; rather,
individual states that were most affected implemented lockdown, as determined by their
respective governors. Second, several hotspots were identified across the country, developing at
different times and with different regulations, further increasing the spread of the virus. Third,
politics had played a major role in the handling of the pandemic. The only non-pharmaceutical
intervention implemented by the United States was a statewide social distancing measure (72).
India and Brazil with their very highly populated countries also saw a spike in the number of
cases (Figure 8). Brazil reported the first case of COVID-19 at a later date than other countries
(Figure 8). The number of deaths spiked in Brazil because the authorities did not implement a
complete lockdown in the initial phases of the pandemic, resulting in a lag in testing capacity
(73). Due to scarce hospital facilities, India had a high number of death cases, as a result of
which millions of people died without receiving treatment. Conversely, Russia reported a low
number of COVID-19 deaths as compared to severely affected countries, with global authorities
claiming that Russian officials were falsifying the number of COVID-19 cases and deaths (43).
Since the start of the pandemic, the United Kingdom showed the highest number of mortalities in
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Europe. This was due to the high number of confirmed cases that were reported in February and
the late response of the government. The first lockdown was implemented in late March (Figure
21) after Boris Johnson, the prime minister, decided that “herd immunity” was not effective in
controlling the number of deaths (74). Egypt also reported an underestimated number of COVID19 cases and deaths, perhaps due to the low testing capacity. As demonstrated by these various
countries taking the preventative measure of lockdown, the intended impact was to reduce the
number of cases and slow the rate of the epidemic. Lockdown effects depend on how soon the
lockdowns are adopted and on how slowly they are lifted.
Generally speaking, the lockdown strategy has been associated with a decline in the number of
cases and deaths worldwide. Among the Egyptian population in particular, lockdowns have
helped identify key risk factors and clinical outcomes among hospitalized COVID-19 patients.
Machine learning models were fed with data collected from Egyptian cases with confirmed
COVID-19 patients admitted to hospitals affiliated to the GOTHI during the lockdown period for
healthcare practitioners to identify high-risk patients and ideally utilize limited resources to fight
the pandemic. Random forest models identified the most common risk factors and clinical
outcomes and correlated them with disease severity in Egyptian COVID-19 patients.
The results demonstrated that age was associated with the severity of COVID-19. The higher the
age was, the more complex the course of the disease. A study carried out in Japan, South Korea,
China, Singapore, Canada, and Italy showed that the number of COVID-19 patients and the risk
of severe disease increases with increasing age (75). In this study, the age group of 60 years were
severely affected by the outcomes of COVID-19 and had higher mortality rates. This is due to
the weakening of the immune system in older patients. Thus, older people are more susceptible
to developing an infection, resulting in them being less able to determine the disease and the
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outcomes of COVID-19 (76). This suggests that older people should receive priority in getting
the required protective care.
There was a strong correlation between individuals in contact with patients and developing
severe COVID-19 complications. People in close proximity with COVID-19 patients are at a
higher risk of becoming infected and potentially infecting others (77). It is important to monitor
contacts after exposure to an infected person to eliminate the spread of the virus among others.
Our options are limited in preventing the spread of the virus as the economy cannot tolerate the
burden of another lockdown period. However, AI can help us carry out contact tracing to identify
the contacts and isolate them until further investigation is carried out. Another method to prevent
the transmission and severity of the virus is by implementing universal facial masking to slow
down the transmission of the virus and generate immunity among the people (78).
There are other factors which play a role in the severity of COVID-19. One of these factors is
pre-existing comorbidities in COVID-19 patients. The Centers for Disease Control and
Prevention (CDC) shows that there are currently suspected comorbidities that leads to poor
prognosis if a patient contracted COVID-19 such as chronic lung disease, moderate to severe
asthma, serious heart condition, severe obesity, hypertension, diabetes, and chronic kidney
disease in an immunocompromised state (79). In our study, severe COVID-19 patients were
found to have pre-existing comorbidities.
Comorbidities were analyzed by the RF classification model, where renal disease and cardiac
disease were the most commonly found comorbidities to raise a patient's risk for developing
severe COVID-19. Patients with preexisting kidney disease are at a higher risk of developing
undesirable outcomes from COVID-19. A study published by Mount Sinai found that out of
3993 hospitalized patients, 46% of patients with COVID-19 developed acute kidney injury and
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19% of these patients ended up on dialysis, as a result of COVID-19 (80). COVID-19 results in
cardiovascular morbidity and mortality among patients. A significant number of hospitalized
COVID-19 patients were found to develop myocardial injury associated with worse disease
prognosis and high mortality rate (81).
Low oxygen levels showed the highest crucial clinical outcome in COVID-19 patients, normal
oxygen saturation in children and adults is between 95% to 100%. Oxygen saturation in COVID19 patients is defined as saturation lower than 90% oxygen, requiring patients to start oxygen
therapy in order to counter adverse effects (82). In this study, oxygen saturation was strongly
correlated with clinical outcomes of COVID-19 patients. Most patients with SaO2 <85% were
severe patients and needed oxygen support. Our results may help guide clinical management of
severe COVID-19 patients particularly in settings that are limited in medical resources.
In COVID-19, there are immunological, inflammatory, and coagulatory responses. Each of these
markers helps doctors know the stage of the disease. In this study, I evaluated the association of
blood biomarkers levels and COVID-19 severity. Using RF models, I found that the highest
predictive blood biomarker for the severity of COVID-19 was ferritin levels. Ferritin is
responsible for storing iron in the body, and high levels of ferritin results in a cytokine storm and
is a major factor for COVID-19 pathogenesis (83). Our study concluded that high levels of
ferritin are associated with increased illness severity and high fatality rates in COVID-19 patients
as shown in figure 27. Abnormal levels of ferritin in COVID-19 patients are linked to a higher
risk of liver injury and severe illness (84). D-dimer tests are used to determine the presence of
pulmonary embolism or deep vein thrombosis, and a normal value of D-dimer is < 250 ng/mL
(85). In figure 28, there was a significant increase in D-dimer levels in critical patients when
compared to non-critical patients. In COVID-19, an elevated level of D-dimer results in a
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thrombo inflammatory process resulting in abnormal blood clotting. It is vital to monitor the
levels of D-dimer in COVID-19 patients, to detect the presence of thrombotic complications
early on; therefore, protective measure are recommended to eliminate the risk of hemorrhage and
reduce thromboembolism, reducing the severity and mortality rate of COVID-19 (86). One of the
most significant biological biomarkers in assessing COVID-19 is the C-reactive protein (CRP)
test. CRP is produced in the liver as a response to inflammation. CRP levels are elevated in
severe COVID-19 cases when compared to mild or non-severe patients (18).
Our current study revealed that the most significant biological biomarker in assessing COVID-19
was ferritin. The increase in ferritin levels caused a cytokine storm which resulted in
inflammation increasing the levels of CRP (87). Moreover, the high inflammation resulted in
internal bleeding and the formation of blood clots, hence increasing the levels of D-dimer (85).
This study revealed that age, comorbidities, and blood test results are strong predictors for the
course of the disease in COVID-19 patients. These biomarkers help clinicians reach a diagnosis,
indicate disease progression, help in hospital admission criteria, and predict severity of disease
among patients.
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Conclusion and Future Work
To conclude, this thesis focuses on the new pandemic disease COVID-19. There has been
extensive research done to understand the pathogenesis, mechanism of action, and effective
treatment strategies for COVID-19. Several countries were severely affected by the new
pandemic resulting in several protective measures put by The World Health Organization and
governments to control the spread of COVID-19. The present study suggests that nonpharmaceutical interventions such as lockdown strategies taken early on during a pandemic can
reduce the number of cases and deaths, containing the spread of the virus. Our study also reveals
that investigating risk factors and most prominent clinical features among COVID-19 Egyptian
patients leads to better preventive measures taken, lowering the mortality rates. Several vaccines
have shown potential effects against the virus, but with the fast mutation and different novel
variants associated with the severity/or transmissibility of the virus, it is difficult to secure the
world against this virus. Therefore, our only option is to identify high-risk patients using
predictive models to help healthcare practitioners allocate hospital resources and hospital
capacity planning.
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Using the data obtained can help create an online tool for hospitals, health care, and patients to
calculate a patient's risk requiring hospitalization after being diagnosed with COVID-19. This
can provide an insight into diseases severity and assist doctors in providing the optimum
healthcare for patients.

82

References

References
1.

Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19)
outbreak. J Autoimmun. 2020;109:102433.

2.

Countries where Coronavirus has spread - Worldometer [Internet]. [cited 2021 Nov 17]. Available
from: https://www.worldometers.info/coronavirus/countries-where-coronavirus-has-spread/

3.

Gao Y, Ding M, Dong X, Zhang J, Kursat Azkur A, Azkur D, et al. Risk factors for severe and critically ill
COVID-19 patients: A review. Allergy. 2021;76(2):428–55.

4.

International Committee on Taxonomy of Viruses (ICTV) [Internet]. International Committee on
Taxonomy of Viruses (ICTV). [cited 2020 Apr 21]. Available from: https://talk.ictvonline.org/

5.

Yang D, Leibowitz JL. The structure and functions of coronavirus genomic 3′ and 5′ ends. Virus Res.
2015 Aug 3;206:120–33.

6.

Coronaviruses and Acute Respiratory Syndromes (COVID-19, MERS, and SARS) - Infectious Diseases
[Internet]. MSD Manual Professional Edition. [cited 2020 Apr 19]. Available from:
https://www.msdmanuals.com/professional/infectious-diseases/respiratory-viruses/coronaviruses-andacute-respiratory-syndromes-covid-19,-mers,-and-sars

7.

Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation and Treatment
Coronavirus (COVID-19). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020
[cited 2020 Apr 19]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK554776/

8.

How do SARS and MERS compare with COVID-19? [Internet]. 2020 [cited 2021 Nov 17]. Available from:
https://www.medicalnewstoday.com/articles/how-do-sars-and-mers-compare-with-covid-19

9.

El-Duah P, Sylverken A, Owusu M, Yeboah R, Lamptey J, Oppong Frimpong Y, et al. Potential
Intermediate Hosts for Coronavirus Transmission: No Evidence of Clade 2c Coronaviruses in Domestic
Livestock from Ghana. Trop Med Infect Dis [Internet]. 2019 Feb 10 [cited 2020 Apr 19];4(1). Available
from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473935/

10.

Friend T, Stebbing J. What is the intermediate host species of SARS-CoV-2? Future Virol. 2021 Mar
1;16(3):153–6.

11.

Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, et al. Genome Composition and Divergence of the
Novel Coronavirus (2019-nCoV) Originating in China. Cell Host Microbe. 2020 Mar 11;27(3):325–8.

12.

Mousavizadeh L, Ghasemi S. Genotype and phenotype of COVID-19: Their roles in pathogenesis. J
Microbiol Immunol Infect [Internet]. 2020 Mar 31 [cited 2020 Apr 19]; Available from:
http://www.sciencedirect.com/science/article/pii/S1684118220300827

13.

Hardenbrook NJ, Zhang P. A structural view of the SARS-CoV-2 virus and its assembly. Curr Opin Virol.
2022 Feb 1;52:123–34.

83

References
14.

Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry
Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr
16;181(2):271-280.e8.

15.

Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Virol J. 2019 May
27;16(1):69.

16.

Khan M, Shah N, Mushtaq H, Jehanzeb V. Profiling Laboratory Biomarkers Associated with COVID-19
Disease Progression: A Single-Center Experience. Int J Microbiol. 2021 Feb 11;2021:e6643333.

17.

Keddie S, Ziff O, Chou MKL, Taylor RL, Heslegrave A, Garr E, et al. Laboratory biomarkers associated
with COVID-19 severity and management. Clin Immunol Orlando Fla. 2020 Dec;221:108614.

18.

Ali N. Elevated level of C‐reactive protein may be an early marker to predict risk for severity of
COVID‐19. J Med Virol. 2020 Jun 9;10.1002/jmv.26097.

19.

Sun H, Guo P, Zhang L, Wang F. Serum Interleukin-6 Concentrations and the Severity of COVID-19
Pneumonia: A Retrospective Study at a Single Center in Bengbu City, Anhui Province, China, in January
and February 2020. Med Sci Monit Int Med J Exp Clin Res. 2020 Nov 11;26:e926941-1-e926941-6.

20.

Marimuthu AK, Anandhan M, Sundararajan L, Chandrasekaran J, Ramakrishnan B. Utility of various
inflammatory markers in predicting outcomes of hospitalized patients with COVID-19 pneumonia: A
single-center experience. Lung India. 2021 Oct;38(5):448–53.

21.

Henry BM, Aggarwal G, Wong J, Benoit S, Vikse J, Plebani M, et al. Lactate dehydrogenase levels
predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis. Am J Emerg
Med. 2020 Sep;38(9):1722–6.

22.

Malone B, Urakova N, Snijder EJ, Campbell EA. Structures and functions of coronavirus replication–
transcription complexes and their relevance for SARS-CoV-2 drug design. Nat Rev Mol Cell Biol. 2022
Jan;23(1):21–39.

23.

de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging
coronaviruses. Nat Rev Microbiol. 2016;14(8):523–34.

24.

Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol. 2020 Apr 9;1–
2.

25.

Williams AE, Chambers RC. The mercurial nature of neutrophils: still an enigma in ARDS? Am J Physiol Lung Cell Mol Physiol. 2014 Feb 1;306(3):L217–30.

26.

Kong SL, Chui P, Lim B, Salto-Tellez M. Elucidating the molecular physiopathology of acute respiratory
distress syndrome in severe acute respiratory syndrome patients. Virus Res. 2009 Nov;145(2):260–9.

27.

Liu M, Yokomizo T. The role of leukotrienes in allergic diseases. Allergol Int. 2015 Jan 1;64(1):17–26.

28.

Adedeji AO, Severson W, Jonsson C, Singh K, Weiss SR, Sarafianos SG. Novel Inhibitors of Severe Acute
Respiratory Syndrome Coronavirus Entry That Act by Three Distinct Mechanisms. J Virol. 2013
Jul;87(14):8017–28.

84

References
29.

Du L, He Y, Zhou Y, Liu S, Zheng B-J, Jiang S. The spike protein of SARS-CoV — a target for vaccine and
therapeutic development. Nat Rev Microbiol. 2009;7(3):226–36.

30.

Xia S, Zhu Y, Liu M, Lan Q, Xu W, Wu Y, et al. Fusion mechanism of 2019-nCoV and fusion inhibitors
targeting HR1 domain in spike protein. Cell Mol Immunol. 2020 Feb 11;1–3.

31.

Hwang Y-C, Lu R-M, Su S-C, Chiang P-Y, Ko S-H, Ke F-Y, et al. Monoclonal antibodies for COVID-19
therapy and SARS-CoV-2 detection. J Biomed Sci. 2022 Jan 4;29(1):1.

32.

Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, et al. Analysis of therapeutic targets for SARS-CoV-2
and discovery of potential drugs by computational methods. Acta Pharm Sin B [Internet]. 2020 Feb 27
[cited 2020 Apr 29]; Available from:
http://www.sciencedirect.com/science/article/pii/S2211383520302999

33.

Ni W, Yang X, Yang D, Bao J, Li R, Xiao Y, et al. Role of angiotensin-converting enzyme 2 (ACE2) in
COVID-19. Crit Care. 2020 Jul 13;24:422.

34.

Zhang H, Baker A. Recombinant human ACE2: acing out angiotensin II in ARDS therapy. Crit Care. 2017
Dec 13;21(1):305.

35.

Jiang S, Hillyer C, Du L. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses.
Trends Immunol [Internet]. 2020 Apr 2 [cited 2020 Apr 29]; Available from:
http://www.sciencedirect.com/science/article/pii/S1471490620300570

36.

Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. Network-based drug repurposing for novel
coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov. 2020 Mar 16;6(1):1–18.

37.

Yadav R, Chaudhary JK, Jain N, Chaudhary PK, Khanra S, Dhamija P, et al. Role of Structural and NonStructural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19. Cells. 2021 Apr 6;10(4):821.

38.

OVERVIEW OF FAVIPIRAVIR AND REMDESIVIR TREATMENT FOR COVID-19 | INTERNATIONAL JOURNAL
OF PHARMACEUTICAL SCIENCES AND RESEARCH [Internet]. 2021 [cited 2022 Feb 8]. Available from:
https://ijpsr.com/bft-article/overview-of-favipiravir-and-remdesivir-treatment-for-covid-19/

39.

Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate Use of Remdesivir
for Patients with Severe Covid-19. N Engl J Med. 2020 Apr 10;0(0):null.

40.

Al-Tawfiq JA, Al-Homoud AH, Memish ZA. Remdesivir as a possible therapeutic option for the COVID19. Travel Med Infect Dis [Internet]. 2020 Mar 5 [cited 2020 May 3]; Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7129391/

41.

Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J, et al. Repurposing of
Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection.
Antimicrob Agents Chemother. 2014 Aug 1;58(8):4885–93.

42.

Biswas P, Hasan MM, Dey D, dos Santos Costa AC, Polash SA, Bibi S, et al. Candidate antiviral drugs for
COVID-19 and their environmental implications: a comprehensive analysis. Environ Sci Pollut Res. 2021
Nov 1;28(42):59570–93.

85

References
43.

Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, et al. Deployment of convalescent
plasma for the prevention and treatment of COVID-19. J Clin Invest [Internet]. 2020 Apr 7 [cited 2020
Apr 30]; Available from: http://www.jci.org/articles/view/138745

44.

Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 Critically Ill Patients With COVID-19
With Convalescent Plasma. JAMA. 2020 Mar 27;

45.

Langhi DM, Santis GCD, Bordin JO. COVID-19 convalescent plasma transfusion. Hematol Transfus Cell
Ther [Internet]. 2020 Apr 17 [cited 2020 Apr 30]; Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164882/

46.

Mascellino MT, Di Timoteo F, De Angelis M, Oliva A. Overview of the Main Anti-SARS-CoV-2 Vaccines:
Mechanism of Action, Efficacy and Safety. Infect Drug Resist. 2021 Aug 31;14:3459–76.

47.

Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. T Cells and MHC Proteins. Mol Biol Cell 4th
Ed [Internet]. 2002 [cited 2022 Jan 16]; Available from:
https://www.ncbi.nlm.nih.gov/books/NBK26926/

48.

Ewer KJ, Barrett JR, Belij-Rammerstorfer S, Sharpe H, Makinson R, Morter R, et al. T cell and antibody
responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Nat Med. 2021 Feb;27(2):270–8.

49.

Oraby T, Tyshenko MG, Maldonado JC, Vatcheva K, Elsaadany S, Alali WQ, et al. Modeling the effect of
lockdown timing as a COVID-19 control measure in countries with differing social contacts. Sci Rep.
2021 Feb 8;11(1):3354.

50.

Bs M, Bs M. COVID-19: An Insight into SARS-CoV-2 Pandemic Originated at Wuhan City in Hubei
Province of China. [cited 2021 Apr 26]; Available from:
https://www.clinmedjournals.org/articles/jide/journal-of-infectious-diseases-and-epidemiology-jide-6146.php?jid=jide

51.

Amaro S. Italy’s coronavirus death toll is more than double China’s — this might be why [Internet].
CNBC. 2020 [cited 2021 Apr 26]. Available from: https://www.cnbc.com/2020/03/27/why-coronavirusdeaths-are-higher-in-italy-spain-than-in-china.html

52.

McCann A, Popovich N, Wu J. Italy’s Virus Shutdown Came Too Late. What Happens Now? The New
York Times [Internet]. 2020 Apr 5 [cited 2021 Apr 26]; Available from:
https://www.nytimes.com/interactive/2020/04/05/world/europe/italy-coronavirus-lockdownreopen.html

53.

Gupta M, Mohanta SS, Rao A, Parameswaran GG, Agarwal M, Arora M, et al. Transmission dynamics of
the COVID-19 epidemic in India and modeling optimal lockdown exit strategies. Int J Infect Dis. 2021
Feb 1;103:579–89.

54.

MENA-Covid-19-Survey-Egypt-January-28-2021-1.pdf [Internet]. [cited 2021 Apr 28]. Available from:
https://www.brookings.edu/wp-content/uploads/2021/01/MENA-Covid-19-Survey-Egypt-January-282021-1.pdf

86

References
55.

Castle S, Landler M. A Claim of Herd Immunity Reignites Debate Over U.K. Covid Policy. The New York
Times [Internet]. 2021 Nov 24 [cited 2022 Feb 8]; Available from:
https://www.nytimes.com/2021/11/24/world/europe/uk-virus-herd-immunity.html

56.

Thüsen J von der, Eerden M van der. Histopathology and genetic susceptibility in COVID-19
pneumonia. Eur J Clin Invest [Internet]. [cited 2020 May 3];n/a(n/a). Available from:
https://onlinelibrary.wiley.com/doi/abs/10.1111/eci.13259

57.

Kang Z, Luo S, Gui Y, Zhou H, Zhang Z, Tian C, et al. Obesity is a potential risk factor contributing to
clinical manifestations of COVID-19. Int J Obes. 2020 Dec;44(12):2479–85.

58.

O’Driscoll M, Ribeiro Dos Santos G, Wang L, Cummings DAT, Azman AS, Paireau J, et al. Age-specific
mortality and immunity patterns of SARS-CoV-2. Nature. 2021 Feb;590(7844):140–5.

59.

Quiroz-Juárez MA, Torres-Gómez A, Hoyo-Ulloa I, León-Montiel R de J, U’Ren AB. Identification of highrisk COVID-19 patients using machine learning. PLOS ONE. 2021 Sep 20;16(9):e0257234.

60.

Braithwaite I, Callender T, Bullock M, Aldridge RW. Automated and partly automated contact tracing: a
systematic review to inform the control of COVID-19. Lancet Digit Health. 2020 Nov 1;2(11):e607–21.

61.

Mahdavi M, Choubdar H, Zabeh E, Rieder M, Safavi-Naeini S, Jobbagy Z, et al. A machine learning
based exploration of COVID-19 mortality risk. PLOS ONE. 2021 Jul 2;16(7):e0252384.

62.

M S, Joy J. An Introduction to Machine Learning. Sreeraj M; 2019. 137 p.

63.

Explore the Spread of Covid-19 [Internet]. [cited 2022 Feb 6]. Available from:
https://jgassen.shinyapps.io/tidycovid19/

64.

owid/covid-19-data [Internet]. GitHub. [cited 2020 Dec 3]. Available from:
https://github.com/owid/covid-19-data

65.

CSSEGISandData. CSSEGISandData/COVID-19 [Internet]. 2020 [cited 2020 Dec 3]. Available from:
https://github.com/CSSEGISandData/COVID-19

66.

COVID-19 Government Measures Dataset - Humanitarian Data Exchange [Internet]. [cited 2021 Jan 3].
Available from: https://data.humdata.org/dataset/acaps-covid19-government-measures-dataset

67.

Meo SA, Abukhalaf AA, Alomar AA, AlMutairi FJ, Usmani AM, Klonoff DC. Impact of lockdown on
COVID-19 prevalence and mortality during 2020 pandemic: observational analysis of 27 countries. Eur J
Med Res. 2020 Nov 10;25(1):56.

68.

Shadmi E, Chen Y, Dourado I, Faran-Perach I, Furler J, Hangoma P, et al. Health equity and COVID-19:
global perspectives. Int J Equity Health. 2020 Jun 26;19:104.

69.

Tao J, Ma Y, Luo C, Huang J, Zhang T, Yin F. Summary of the COVID-19 epidemic and estimating the
effects of emergency responses in China. Sci Rep. 2021 Jan 12;11(1):717.

70.

Modi C, Böhm V, Ferraro S, Stein G, Seljak U. Estimating COVID-19 mortality in Italy early in the COVID19 pandemic. Nat Commun. 2021 May 12;12(1):2729.

87

References
71.

Coronavirus (COVID-19) regulations and guidance: what they mean for you | nidirect [Internet]. 2020
[cited 2022 Feb 6]. Available from: https://www.nidirect.gov.uk/articles/coronavirus-covid-19regulations-and-guidance-what-they-mean-you

72.

Siedner MJ, Harling G, Reynolds Z, Gilbert RF, Haneuse S, Venkataramani AS, et al. Social distancing to
slow the U.S. COVID-19 epidemic: longitudinal pretest-posttest comparison group study [Internet].
medRxiv; 2020 [cited 2022 Feb 6]. p. 2020.04.03.20052373. Available from:
https://www.medrxiv.org/content/10.1101/2020.04.03.20052373v3

73.

Silva L, Figueiredo Filho D, Fernandes A. The effect of lockdown on the COVID-19 epidemic in Brazil:
evidence from an interrupted time series design. Cad Saúde Pública [Internet]. 2020 Oct 19 [cited 2022
Feb 6];36. Available from: http://www.scielo.br/j/csp/a/k5KKkRb9n9xZnkB8wNxsfkf/?lang=en

74.

Zenone M, Snyder J, Marcon A, Caulfield T. Analyzing natural herd immunity media discourse in the
United Kingdom and the United States. PLOS Glob Public Health. 2022 Jan 12;2(1):e0000078.

75.

Davies NG, Klepac P, Liu Y, Prem K, Jit M, Eggo RM. Age-dependent effects in the transmission and
control of COVID-19 epidemics. Nat Med. 2020 Aug;26(8):1205–11.

76.

Bajaj V, Gadi N, Spihlman AP, Wu SC, Choi CH, Moulton VR. Aging, Immunity, and COVID-19: How Age
Influences the Host Immune Response to Coronavirus Infections? Front Physiol [Internet]. 2021 [cited
2022 Feb 4];11. Available from: https://www.frontiersin.org/article/10.3389/fphys.2020.571416

77.

Ge Y, Martinez L, Sun S, Chen Z, Zhang F, Li F, et al. COVID-19 Transmission Dynamics Among Close
Contacts of Index Patients With COVID-19: A Population-Based Cohort Study in Zhejiang Province,
China. JAMA Intern Med. 2021 Oct 1;181(10):1343–50.

78.

Gandhi M, Rutherford GW. Facial Masking for Covid-19 — Potential for “Variolation” as We Await a
Vaccine. N Engl J Med. 2020 Oct 29;383(18):e101.

79.

CDC. COVID-19 and Your Health [Internet]. Centers for Disease Control and Prevention. 2020 [cited
2021 Oct 24]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/need-extraprecautions/people-with-medical-conditions.html

80.

Chan L, Chaudhary K, Saha A, Chauhan K, Vaid A, Zhao S, et al. AKI in Hospitalized Patients with COVID19. J Am Soc Nephrol JASN. 2021 Jan;32(1):151–60.

81.

Basu-Ray I, Almaddah N k, Adeboye A, Soos MP. Cardiac Manifestations Of Coronavirus (COVID-19). In:
StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 [cited 2022 Feb 4]. Available
from: http://www.ncbi.nlm.nih.gov/books/NBK556152/

82.

Mejía F, Medina C, Cornejo E, Morello E, Vásquez S, Alave J, et al. Oxygen saturation as a predictor of
mortality in hospitalized adult patients with COVID-19 in a public hospital in Lima, Peru. PLOS ONE.
2020 Dec 28;15(12):e0244171.

83.

Habib HM, Ibrahim S, Zaim A, Ibrahim WH. The role of iron in the pathogenesis of COVID-19 and
possible treatment with lactoferrin and other iron chelators. Biomed Pharmacother. 2021 Apr
1;136:111228.

88

References
84.

Hussein AM, Taha ZB, Gailan Malek A, Akram Rasul K, Qasim Hazim D, Jalal Ahmed R, et al. D-Dimer
and Serum Ferritin as an Independent Risk Factor for Severity in COVID-19 Patients. Mater Today Proc
[Internet]. 2021 Apr 13 [cited 2021 Nov 29]; Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043615/

85.

Yu H-H, Qin C, Chen M, Wang W, Tian D-S. D-dimer level is associated with the severity of COVID-19.
Thromb Res. 2020 Nov;195:219–25.

86.

He X, Yao F, Chen J, Wang Y, Fang X, Lin X, et al. The poor prognosis and influencing factors of high Ddimer levels for COVID-19 patients. Sci Rep. 2021 Jan 19;11(1):1830.

87.

Biomarkers of cytokine storm as red flags for severe and fatal COVID-19 cases: A living systematic
review and meta-analysis [Internet]. [cited 2022 Feb 23]. Available from:
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0253894

89

